Taking tesamorelin is linked to less belly fat in people with HIV who have body shape changes. This finding is from the abstract summary - full study details were not available

Scientific Claim

Tesamorelin use is associated with improvements in visceral fat adiposity in HIV-1-infected patients with lipodystrophy.

Original Statement

“Tesamorelin, an injectable growth hormone-releasing factor analogue, has been shown to improve visceral fat adiposity”

From study:Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy

Evidence Quality Assessment

Claim Status

overstated

Study Design Support

Design cannot support claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The abstract uses causal language ('improve'), but the study design is unknown (not confirmed as RCT), so the claim should use 'associated with' instead of 'improves'.

Evidence from Studies

Supporting (1)

Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy

Case-Control Study

Human

2011 Jan

Contradicting (0)

No contradicting evidence found

Source Study

Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy

Score: 20

DOI: 10.1586/eem.10.83

Similar Assertions

Tesamorelin doesn't significantly change the fat under the skin in people with HIV-related body shape changes. This finding is from the abstract summary - full study details were not available

94%

Continuing tesamorelin for a full year helps HIV patients with belly fat lose nearly 18% of their dangerous internal belly fat, with no loss of benefit over time.

89%

Tesamorelin helps lower blood fat levels in people with HIV-related body changes. This finding is from the abstract summary - full study details were not available

89%

A hormone treatment called tesamorelin doesn't change the fat under the skin in people with HIV who have excess belly fat after six months of treatment.

88%

A hormone treatment called tesamorelin decreases belly fat by 42 square centimeters more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.

87%